Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

February 3, 2023 BIZ PEOPLE 

Yale School of Public Health to get new dean

PHOTO | CONTRIBUTED  Dr. Megan L. Ranney

Clinician and scientist Dr. Megan L. Ranney will become dean of the Yale School of Public Health on July 1. 

Ranney currently serves as the deputy dean of the Brown University School of Public Health and has been on the faculty there since 2008. She is also a professor of behavioral and social science, the Warren Alpert Endowed Professor of Emergency Medicine at Brown University’s Alpert Medical School, and the founding director of the Brown-Lifespan Center for Digital Health. 

Yale President Peter Salovey said Ranney has received several awards for her teaching, research and community service.

“Professor Ranney has led transformative initiatives that bridge research and curriculum development, clinical care improvement, community engagement and national outreach,” Salovey said in an announcement.

Ranney’s background includes working with various groups to address health issues such as firearm injuries and COVID-19.

Ranney will replace interim Dean Melinda Pettigrew, who started in the role in July 2022 to replace outgoing Dean Dr. Sten Vermund, who returned to full-time teaching and research.


Rallybio appoints new chief financial officer

Jonathan I. Lieber

New Haven-based biotech company Rallybio Corporation announced that Jonathan I. Lieber became the company’s new chief financial officer as of Feb. 1.

Lieber succeeds Jeffrey Fryer, Rallybio’s co-founder and CFO, who is leaving the company as of Feb. 15.  

Lieber has more than three decades of experience as a chief financial officer for public and private life sciences companies and as an investment banker. He most recently served as the CFO of Applied Genetic Technologies Corporation, a publicly-traded biotechnology gene therapy company focused on rare diseases.

Rallybio CEO Martin Mackay said Lieber has “an outstanding record of leadership in finance, capital raising, long-range strategic planning, and operations, as well as investor relations.”

Rallybio is a clinical-stage biotech. Since launching in 2018, it has built a portfolio of drug candidates to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. 

Sign up for Enews


Order a PDF